Perrigo Announces FDA Final Approval For Desloratadine

Links shared publicly online about this topic.

0
total visits

Perrigo Announces FDA Final Approval For Desloratadine

Perrigo Company (Nasdaq: PRGO;TASE) announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for Desloratadine table

View full resource at medicalnewstoday.com

Tags: Allergy Medication, Antihistamine, Diet and Nutrition, Drug, FDA, Clarinex, Aerius

Most Recently Shared on December 30, 2011 at 8:25 pm By:

Gunter Wessels

Perrigo Announces FDA Final Approval For Desloratadine http://t.co/IPcQf7Sk

5 months ago...

Retweet

Favorite

Also Shared By:

FDA approves Perrigo's ANDA for OTC Miconazole Nitrate Vaginal Cream and Suppository

news-medical.net — “Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter (OTC) Miconazole Nitrate Vaginal Cream and Suppository, a generic to Monistat® -1 Combination Pack. Perrigo expects to begin shipping immediately.” View full resource at news-medical.net

Most Recently Shared on June 4, 2010 at 4:59 am By:

News-Medical.Net Health News

FDA approves Perrigo's ANDA for OTC Miconazole Nitrate Vaginal Cream and Suppository: Perrigo Company today announ... http://bit.ly/a8gF0p

2 years ago...

Retweet

Favorite

Perrigo, Cobrek Pharmaceuticals receive FDA approval for generic Evoclin Foam 1%

news-medical.net — “Perrigo Company today announced that together with its partner Cobrek Pharmaceuticals, Inc. final approval has been received from the U.S. Food and Drug Administration to manufacture and market Clindamycin Phosphate Foam 1%, a generic version of Evoclin® Foam 1% of Stiefel. As the ANDA was first to file with a Paragraph IV certification against Evoclin®, 180 days of generic exclusivity was granted by the U.S. Food and Drug Administration.” View full resource at news-medical.net